Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Antengene Corporation Limited ( (HK:6996) ) has shared an announcement.
Antengene Corporation Limited announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug Application for XPOVIO® (selinexor) to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant. This approval enhances Antengene’s market presence in Malaysia and strengthens its position in the biotech industry by expanding the therapeutic use of its lead asset, XPOVIO®, in the Asia Pacific region.
The most recent analyst rating on (HK:6996) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.
More about Antengene Corporation Limited
Antengene Corporation Limited is a global, R&D-driven biotech company focused on developing first-in-class and best-in-class therapeutics for diseases with significant unmet medical needs. The company’s pipeline includes several programs from preclinical to commercial stages, such as ATG-022, ATG-037, ATG-101, ATG-031, and ATG-042, and it has developed the AnTenGager™ platform for broad applicability across various medical indications. Antengene has obtained 32 investigational new drug approvals in the U.S. and Asia and submitted new drug applications in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in multiple regions and included in national insurance schemes in several markets.
Average Trading Volume: 2,750,935
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.79B
Learn more about 6996 stock on TipRanks’ Stock Analysis page.